Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation

Recruiting

Phase 1

QUAIL-100Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation

Sponsor:

Laguna Biotherapeutics, Inc.

Code:

NCT07573111

Conditions

Acute Leukemia

Myelodysplastic Syndrome

Eligibility Criteria

Sex: All

Age: 1 - 39

Healthy Volunteers: Not accepted

Interventions

QUAIL-100

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-08. This information was provided to ClinicalTrials.gov by Laguna Biotherapeutics, Inc. on 2026-08-04.